Perspective Therapeutics (CATX) Acquisitions (2023)
Perspective Therapeutics' (CATX) quarterly Acquisitions came in at $2.7 million in Q1 2023.
Analysis
Perspective Therapeutics (CATX) Acquisitions (2023) Analysis & Trends
Perspective Therapeutics has disclosed Acquisitions across 1 years of filings, most recently posting $2.7 million for Q1 2023.
- In Q1 2023, Acquisitions changed N/A year-over-year to $2.7 million; the TTM figure through Dec 2023 stood at $2.7 million (changed N/A YoY), while the FY2023 annual figure was $2.7 million, changed N/A from the prior year.
- Acquisitions came in at $2.7 million for Q1 2023 at Perspective Therapeutics.
- In the past five years, Acquisitions ranged from a high of $2.7 million in Q1 2023 to a low of $2.7 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 11.21 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Perspective Therapeutics | 358.23 Mn | 358.23 Mn | - | - |